Glioma

The National Comprehensive Cancer Network (NCCN) has updated its clinical practice guidelines to include Modeyso (dordaviprone) as an appropriate option for a rare recurrent…

Researchers may have found a way to halt the spread of aggressive brain tumors by targeting the environment around the cancer cells. A new study…

Enrollment is now open in a U.S. clinical trial testing the immune-modulating therapy CUE-102 in people with recurrent glioblastoma, an aggressive form of glioma…

The U.S. Food and Drug Administration (FDA) will allow Hemispherian to test its first-in-class experimental therapy for glioblastoma in a Phase 1 clinical trial.

A committee of the European Medicines Agency (EMA) is recommending that the daily oral therapy Voranigo (vorasidenib) be approved in the European Union to treat…

A study found that analyzing levels of immune cells and related molecules in the bloodstream of people with glioma can accurately distinguish between different…

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MB-101, a CAR T-cell therapy being developed by Mustang Bio to…

July 16 marks Glioblastoma Awareness Day (GBM Day), an annual observance dedicated to raising awareness about the rare and aggressive form of brain cancer, promoting…

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GLIX1, a cancer treatment now in the preclinical stages of development, as…

Reyobiq (Rhenium Re186 Obisbemeda), an experimental radiation therapy being developed by Plus Therapeutics, has been cleared by the U.S. Food and Drug Administration (FDA)…